Trial Profile
A Phase I Dose-escalation Study of VEGF-Antisense Oligonucleotide (VEGF-AS) in Patients with Advanced Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2016
Price :
$35
*
At a glance
- Drugs Veglin (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 29 Oct 2004 New trial record.